Business meeting to consider S.1067, to amend the Federal Food, Drug, and Cosmetic Act with respect to citizen petitions, S.1114, to amend the Federal Food, Drug, and Cosmetic Act with respect to the 180-day exclusivity period, S.1214, to set forth limitations on exclusive approval or licensure of drugs designated for rare diseases or conditions, S.1339, to provide for increased oversight of entities that provide pharmacy benefit management services on behalf of group health plans and health insurance coverage, and other pending calendar business.